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level (Figure 1 ) with hypertelorism and a supernumerary bone at the frontal level. Th e fetus showed a small thorax at the expense of cervical kyphosis and dorsal level scoliosis (Figure 2 ) with subjective narrowing of the medullar canal. We also found suspicion of bladder exstrophy and a bivascular umbilical cord. Suspecting a chromosomal anomaly and/or craniosynostosis, an amniocentesis was carried out for a karyotype test and to perform a genetic molecular craniosynostosis study -this was sent to the fetal Medicine Reference Unit at San Cecilio Hospital (Granada, Spain) for counselling and second opinion, which confi rmed our ultrasound diagnosis. Th e genetic test revealed a normal karyotype and the technical array showed heterozygosity of the c870 Ͼ T mutation (p.Trp 290Cys) in the FGFR2 gene, compatible with Type II Pfeiff er syndrome.
Because of the poor prognosis, the patient decided on a termination of the pregnancy with an anatomopathological study, which confi rmed the prenatal fi ndings.
Discussion
Th e prenatal diagnosis of cranial deformities (Park et al. 1996 ) is associated with diverse syndromes: a strawberry-shaped cranium is associated with trisomy 18 (T18); a lemon-shaped cranium with neural tube defects; frontal prominence with achondroplasia and the Russell -Silver syndrome; trigonocephaly with Jacobsen syndrome; brachycephaly with trisomy 21 (T21); chondrodysplasia, the Cornelia de Lange syndrome and cranial asymmetry with amniotic band syndrome and the Wolf -Hirschhorn syndrome. A cloverleaf-shaped cranium is present in thanatophoric dysplasia (not associated with craniosynostosis); or syndromes that indeed are associated with craniosynostosis such as Apert, Carpenter, Crouzon, Jackson Weiss and Pfeiff er syndromes (Benacerraf et al. 2000) .
Pfeiff er syndrome was fi rst described by Pfeiff er in 1964 (Park et al. 1996) and then by Cohen in 1993, based on phenotype severity, describing three types: Type I, Type II and Type III. Type I is associ- ated with mild manifestations, having normal neurological development and a good prognosis. Type II comprises a cloverleaf-shaped cranium, severe proptosis, arm and feet abnormalities and severely compromised neurological development. Type III is similar to Type II but without the cloverleaf-shaped cranium (Oyamada et al. 2003) . Th e grave neurological deterioration, together with the severe visceral manifestations of Type II and Type III generally lead to death within the fi rst few years of life (Lee et al. 2010) .
Even although the ultrasound analysis makes us suspect the pathology, there are incomplete syndromes (as in this case, no observed hand and feet deformities), thus it is the genetic analysis which gives the diagnosis. Apert, Crouzon, Jackson Weiss and Pfeiff er syndromes are associated with the mutation of fi broblast growth factor receptor 1 (FGFR1 on chromosome 8) and fi broblast growth factor receptor 2 (FGFR2 on chromosome 10) (Gripp et al. 1998) . Pfeiff er syndrome Type I is a dominant autosomal inheritance mutation in either FGFR1 or FGFR2; whereas Types II and III are sporadic mutations in FGFR2 (Piccione et al. 2009 ); these mutations have been associated with the elevated age of the parents, especially of the father, since these mutations appear to off er a selective advantage for sperm survival (Goriely et al. 2003) . Nevertheless, the risk of the following child having the syndrome is minimal and the descendents of the patient aff ected by this condition have a 50 -60% chance of transmitting it to their descendents, given the dominant character of this gene.
Conclusion
Prenatal diagnosis of cranial malformations, with suspected premature fusion of the sutures, should raise suspicion of Pfeiff er syndrome -a diagnosis that can be confi rmed by genetic testing.
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Introduction
Mitochondrial toxicity induced by inhibition of gamma DNA polymerase is an adverse eff ect of nucleoside reverse transcriptase inhibitors (NRTI) and is responsible for a broad spectrum of clinical conditions that include lactic acidosis and hepatic steatosis (Brinkman et al. 1998) . Growing data suggest increased susceptibility during pregnancy (Fleischer et al. 2004 ). Moreover, fatal cases have been reported during the 3rd trimester and with long-term therapy (Luzzati et al. 1999; Sarner and Fakoya 2002; Bristol-Myers Squibb 2001) . Hence, the combination of stavudine and didanosine is currently not recommended throughout gestation (Bristol-Myers Squibb 2001; AIDS info 2012).
We report a case of an HIV-1-infected pregnant woman presenting in the 1st trimester, with symptoms suggesting lactic acidosis and who had been on stavudine and lamivudine for only 5 months.
Case report
A 27-year-old HIV-1-infected nulliparous woman presented with vomiting, nausea, asthenia and anorexia in the 10th week of pregnancy. She had been on antiretroviral (ARV) therapy since the age of 22. At 3 months before pregnancy, and because her viral load was rising, she was switched to stavudine, lamivudine and lopinavir/ ritonavir. At the time of conception, she had a CD4 count of 641 ϫ 10 6 /l and an undetectable viral load ( Ͻ 50 copies/ml). On admission, examination revealed apyrexia, and a normal pulse and respiratory rate. Th ere were no focal signs of hepatitis, pancreatitis or obstetric complications. Investigations showed an AST 21 times the upper limit of the norm (ULN); ALT 13.5 times the ULN; an elevated GGT and LDH (7.5 and 5 ϫ ULN, respectively) and a metabolic acidosis (pH ϭ 7.32), with low bicarbonate (HCO 3 ) and elevated arterial lactate (2.5 ϫ ULN) ( Table I) . Abdominal ultrasound and other tests were in the normal range. She was managed with the diagnosis of lactic acidosis and liver dysfunction probably secondary to NRTI.
ARV therapy was immediately stopped. She was managed with close surveillance, monitoring gasometry and lactate levels, daily. Th e patient was symptom free within 3 days and discharged aft er 15 days in hospital, during which time investigations gradually returned to normal (Table I ). Viral load increased to 175.190 copies/ ml and CD4 dropped to 221 ϫ 10 6 /l. ARV therapy was restarted 4 weeks later, using zidovudine, lamivudine and lopinavir/ritonavir. Subsequently, AST and ALT remained within the normal range throughout the rest of the pregnancy and viral load decreased, becoming undetectable before delivery. An elective caesarean section was performed at 38 weeks and 3 days. Th e apparently healthy infant was also given zidovudine, according to hospital protocol. DNA PCR HIV tests were negative at 48 hours and 2, 4, 6 and 12 months aft er birth.
Discussion
Th e incidence of NRTI-induced lactic acidosis/hepatic steatosis in HIV-infected pregnant women is unknown. Nevertheless, there are three reported cases of maternal death related to stavudine and didanosine use, two associated with fetal death (Bristol-Myers Squibb 2001; Sarner and Fakoya 2002) . Non-fatal cases with this combination have also been described (Mandelbrot et al. 2003) . Th ere is also a reported case of fetal death at 38 weeks ' gestation, with stavudine and lamivudine (Luzzati et al. 1999) . In all cases, the women presented aft er at least 6 months of therapy, with a rapidly progressive disease occurring in the 3rd trimester. Th is is in contrast to our case, in which the onset of the symptomatic disease was in the 1st trimester and only aft er 5 months of stavudine and lamivudine.
NRTI-induced lactic acidosis/hepatic steatosis have similarities to rare but life-threatening syndromes: acute fatty liver of pregnancy (AFLP) and the HELLP syndrome (haemolysis, elevated liver enzymes and low platelets). Data support that both of these are associated with a recessively inherited condition that compromises fatty acid oxidation. Th e same dysfunctional pathway may contribute to the development of NRTI-induced mitochondrial toxicity (AIDS info 2012). In our case report, early gestational age and the absence of specifi c clinical and laboratory features excluded HELLP and AFLP. Th erefore, the diagnosis of NRTI-induced lactic acidosis seemed most likely.
Low levels of ribofl avin may also be involved in the pathogenesis of NRTI-induced mitochondrial toxicity (Luzzati et al. 1999) . Lower levels of this vitamin have been reported in pregnant women compared with non-pregnant women (Vir et al. 1981) . Moreover, ribofl avin has been used to treat lactic acidosis (Mandelbrot et al. 2003; Brinkman et al. 2000) . Likewise, other vitamin B complex elements have been used as therapeutic agents (thiamine, nicotinamide, pyridoxine and dexpanthenol), as well as co-enzyme Q, lcarnitine and vitamin C (Brinkman et al. 2000) . Nevertheless, data in this regard is scarce to support its effi cacy. Indeed, the treatment of this syndrome remains obscure and incidental. Most authors agree on the immediate interruption of antiretroviral drugs and the use of nonspecifi c adequate support measures.
As the benefi t of ARV prophylaxis in reducing transmission of a fatal infection has long been clear, and the combination of stavudine and didanosine always seems to play a central role in the more serious reported cases of lactic acidosis, we decided to restart ARV therapy, replacing stavudine by zidovudine. Th e described derangement did not recur, probably because, as happens in vitro and also in vivo, the relative potency of stavudine in inhibiting mitochondrial gamma DNA polymerase is higher than that of zidovudine.
As pregnancy may enhance HIV-infected women ' s susceptibility to nucleoside analogues lactic acidosis, healthcare professionals should be vigilant for its onset. Nonspecifi c symptoms can easily be undervalued, especially in the 1st trimester. However, they may represent the initial manifestation of a life-threatening syndrome and hence, always require further investigation. 
Introduction
A twin pregnancy with a complete hydatidiform mole and a coexistent healthy fetus (CHMF) is rare. Th e reported incidence is 1 in 22,000 -100,000 pregnancies (Steller et al. 1994) . Complete resorption of molar component of CHMF cases has not been reported so far in the literature.
Case report
A 20-year-old primigravida presented with vaginal bleeding at 10 weeks ' gestation. Th e ultrasound scan (USS) revealed an enlarged heterogenous placenta with cystic changes and a live fetus of approximately 11 weeks (Figure 1a) . Th e initial diff erential diagnoses were partial mole (triploid fetus) and placental mesenchymal dysplasia (diploid fetus). Chorionic villous sampling (CVS) revealed a diploid 46XX karyotype and histopathology showed features of complete mole. Th e absence of p57 on immunochemical staining confi rmed complete mole. Th erefore a diagnosis of twin pregnancy with CHMF was made. Th e couple was counselled regarding the possible complications including miscarriage, pre-term delivery, intrauterine death, antepartum haemorrhage, pre-eclampsia and persistent gestational trophoblastic disease (PTD). Th ey opted to continue with the pregnancy. Th e woman was seen in the antenatal clinic fortnightly with regular scans. All assessments were normal. USS at 16 weeks demonstrated a normal fetus and an enlarged placenta, mostly with marked cystic changes but also a smaller normal looking portion. At 19 weeks, the molar placenta was seen on the anterior and right side of the uterus and the normal placenta was posterior and to the left . Even the normal looking placenta had some cystic changes. On further scans, the molar placenta was seen diminishing in size (Figure 1b) and at 35 weeks, the cystic changes were no longer visible while the normal looking placenta became predominant.
Labour was induced at 37 weeks and the woman delivered a healthy baby (2,845 g) vaginally. Th e placenta (20 ϫ 19 ϫ 2 cm, 931 g) was mottled with white fl ecks and patches but no cystic changes. Histology revealed features of 3rd trimester placenta consisting of haemorrhagic endovasculosis, stem and branch villous vasoocclusive lesions but the molar changes seen earlier on the CVS had been completely reabsorbed.
Serial measurements of postnatal maternal serum β -hCG demonstrated a steady fall to Ͻ 1 IU/L at 6 weeks. Th e woman did not develop PTD on a 6 months follow-up.
Discussion
When a fetus with a molar placenta is seen on USS, the diff erential diagnoses include a singleton gestation consisting of a partial mole (triploid fetus) or a CHMF, i.e. dichorionic twin gestation in which one twin is diploid with a normal placenta and the other twin is a complete hydatidiform mole. Distinguishing partial mole from CHMF (by prenatal testing for fetal karyotype) is important as CHMF has a chance of survival. If fetal karyotype is triploid, termination of pregnancy can be recommended, however if it is diploid, it is not confi rmatory diagnosis of CHMF. DNA polymorphism analysis is the most reliable method but routine molecular analysis is impractical. Recent studies have suggested that the immunohistochemical staining with p57 can distinguish androgenetic conceptuses (complete mole) from biparental ones (normal fetus, partial mole). p57 is a gene which is imprinted with preferential expression on the maternal allele, which will be absent in androgenetic conceptuses and present in biparental ones (Crisp et al. 2003; Kihara et al. 2005) .
Although cytogenetic studies were not performed in our case, the presence of 46XX placental karyotype, absence of p57 on immunohistochemical staining, antenatal histopathological fi ndings and ultrasound demarcation between the normal and molar placenta 
